LONDON, ON, Nov. 11 /PRNewswire/ - Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr. Jean-Claude Tardif, Director of the Research Center at the Montreal Heart Institute, will present data from a Phase IIa clinical trial evaluating VT-111 at the American Heart Association (AHA) Scientific Sessions 2009 conference. The conference will take place in Orlando, Florida from November 14 to 18, 2009.
The presentation entitled, "Viral Anti-inflammatory Treatment of Unstable Coronary Syndromes: The VT-111 Acute Coronary Syndrome Trial," will disclose recent results from a Phase IIa trial evaluating VT-111, a serine protein inhibitor, in patients with Acute Coronary Syndromes receiving coronary stents. Dr. Tardif's presentation is scheduled for Wednesday, November 18, 2009, at 11:00 AM (ET) in Room W304gh of the Orange County Convention Center. A copy of the presentation will be available after the conference on Viron's website, www.vironinc.com.
VT-111, an immune-modulating protein therapeutic, is the world's first viral-derived human therapeutic. It is a novel inhibitor of the monocyte/macrophage influx to sites of injury and has demonstrated potent efficacy in preclinical models of acute injury in which inflammation plays a key role. VT-111 recently completed a Phase IIa trial of 48 patients with Acute Coronary Syndromes receiving coronary stents. In addition to advancing the cardiovascular program with a partner, Viron is moving to conduct appropriate preclinical studies prior to a clinical program to evaluate the effects of VT-111 in solid organ transplantation.
About Viron Therapeutics Inc. (www.vironinc.com)
Viron is a biopharmaceutical company pioneering the development of pathogen proteins, a revolutionary new class of drugs. These drugs leverage strategies evolved by pathogens to inactivate key targets in the human immune system. The Company's proprietary PROSPECT(TM) technology, PROtein Screen for Pathogen-Evolved Combination Therapeutics, is a platform for the discovery of new immune-modulating protein therapeutics. Its significant pipeline of products target critical pathways that have broad application to immune and inflammatory based diseases such as cardiovascular disease and rheumatoid arthritis. VT-111, the Company's lead compound, is in development to treat Acute Coronary Syndromes and solid organ transplant rejection.
CONTACT: Viron Therapeutics Inc., Kevin Sullivan, Vice President, Business
Development, Phone: (519) 858-5120, Fax: (519) 858-5103, E-mail:
firstname.lastname@example.org, www.vironinc.com; Investor Relations, Ross
Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax:
(416) 815-0080, E-mail: email@example.com